Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GXO Logistics Inc (GXO) vs Eli Lilly And Co (LLY) Price & Performance

GXO Logistics IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

GXO Logistics Inc vs Eli Lilly And Co — how do they compare? GXO Logistics Inc trades at $47.96 (market cap $5.37B), while Eli Lilly And Co trades at $1,221.03 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 201.1× GXO Logistics Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.

GXOLLY
Market Cap
$5.37B$1.08T
Sector
IndustrialsHealth
52-Week High
$65.59$1.24K
52-Week Low
$45.52$639.43
Enterprise Value
$10.72B$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GXO Logistics Inc

GXO Logistics trades at $47.98, up 2.17% today, with a bearish technical signal but strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.59 exceeding expectations, and revenue growth to $13.6B in 2026. Recent news highlights CEO commentary on data center growth and business transfers, while margins face pressure.

Outlook is mixed: high P/E of 41.3 suggests premium valuation, but low P/S of 0.4 and 88.9% buy ratings from analysts signal upside potential to a $65.67 consensus target. Risks include margin stagnation and competitive logistics market, requiring monitoring of profit expansion.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GXO Logistics Inc

GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.

Read more on GXO

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY